Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis
Authors' conclusion
Children with RDs are at risk of severe COVID-19 outcomes, while children with JIA taking TNFα inhibitors might be at a lower risk.
Study context
- Population
- Paediatric patients with rheumatic diseases and SARS-CoV-2 infection
- Participants
- 1,501 patients8 cohort studies
- Comparison
- Risk factors (diagnosis, medications) for COVID-19-related hospitalization in children with rheumatic diseases
- Outcome
- COVID-19-related hospitalization
Methodological detailssearches of MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure, 1 December 2019 to 22 January 2024
- Searches of MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure, 1 December 2019 to 22 January 2024
Pooled result
As reported in the abstract
COVID-19-related hospitalization, by risk factor
- Juvenile idiopathic arthritis (JIA) diagnosis, OR
- 0.43 (0.27, 0.68) (95% CI)
- sJIA, OR
- 2.54 (1.01, 6.40) (95% CI)
- GC use, OR
- 5.36 (2.21, 13.04) (95% CI)
- RTX use, OR
- 4.62 (1.87, 11.40) (95% CI)
- MMF use, OR
- 4.17 (1.08, 16.16) (95% CI)
- HCQ use, OR
- 2.97 (1.42, 6.21) (95% CI)
- IL-1 inhibitor use, OR
- 2.28 (1.09, 4.78) (95% CI)
- TNFα inhibitor use, OR
- 0.35 (0.20, 0.66) (95% CI)
Original publication
Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis. Rheumatology (Oxford). Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →